146 related articles for article (PubMed ID: 38437507)
1. CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells.
Mensurado S; Condeço C; Sánchez-Martínez D; Shirley S; Coelho RML; Tirado N; Vinyoles M; Blanco-Domínguez R; Barros L; Galvão B; Custódio N; Gomes da Silva M; Menéndez P; Silva-Santos B
Blood; 2024 Apr; 143(15):1488-1495. PubMed ID: 38437507
[TBL] [Abstract][Full Text] [Related]
2. Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells.
Di Lorenzo B; Simões AE; Caiado F; Tieppo P; Correia DV; Carvalho T; da Silva MG; Déchanet-Merville J; Schumacher TN; Prinz I; Norell H; Ravens S; Vermijlen D; Silva-Santos B
Cancer Immunol Res; 2019 Apr; 7(4):552-558. PubMed ID: 30894378
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.
Kaito Y; Sugimoto E; Nakamura F; Tsukune Y; Sasaki M; Yui S; Yamaguchi H; Goyama S; Nannya Y; Mitani K; Tamura H; Imai Y
Haematologica; 2024 Apr; 109(4):1107-1120. PubMed ID: 37731380
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
5. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
[TBL] [Abstract][Full Text] [Related]
6. Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.
Kearney CJ; Ramsbottom KM; Voskoboinik I; Darcy PK; Oliaro J
Oncoimmunology; 2016 Aug; 5(8):e1196308. PubMed ID: 27622064
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
8. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112).
Pende D; Spaggiari GM; Marcenaro S; Martini S; Rivera P; Capobianco A; Falco M; Lanino E; Pierri I; Zambello R; Bacigalupo A; Mingari MC; Moretta A; Moretta L
Blood; 2005 Mar; 105(5):2066-73. PubMed ID: 15536144
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.
Orleans-Lindsay JK; Barber LD; Prentice HG; Lowdell MW
Clin Exp Immunol; 2001 Dec; 126(3):403-11. PubMed ID: 11737054
[TBL] [Abstract][Full Text] [Related]
11. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A
J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096
[TBL] [Abstract][Full Text] [Related]
12. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
Ingram W; Chan L; Guven H; Darling D; Kordasti S; Hardwick N; Barber L; Mufti GJ; Farzaneh F
Br J Haematol; 2009 Jun; 145(6):749-60. PubMed ID: 19388935
[TBL] [Abstract][Full Text] [Related]
13. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
14. CD155 and CD112 as possible therapeutic targets of
Kaito Y; Hirano M; Futami M; Nojima M; Tamura H; Tojo A; Imai Y
Oncol Lett; 2022 Feb; 23(2):51. PubMed ID: 34992684
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
[TBL] [Abstract][Full Text] [Related]
16. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.
Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R
Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766
[TBL] [Abstract][Full Text] [Related]
18. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells.
Wu K; Wang LM; Liu M; Xiu Y; Hu Y; Fu S; Huang H; Xu B; Xiao H
Cancer Sci; 2021 Aug; 112(8):3233-3242. PubMed ID: 34107135
[TBL] [Abstract][Full Text] [Related]
19. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
20. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.
Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A
Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
